6 But while a number of studies have explored the impact of overweight or obesity on the risk of endometrial cancer, less is known about these trends over time in relation to race and ethnicity ...

The obesity medicine field has gained a new entrant, with AbbVie on Monday announcing it had licensed an experimental weight loss drug from a Danish company that is in a Phase 1 trial.

AbbVie is paying $350 million to join the obesity race. The outlay, plus up to $1.87 billion in milestones, has landed the drugmaker rights to a long-acting amylin analog that is in phase 1 ...

At the forefront of Amgen's growth strategy is its obesity program, headlined by MariTide. This potential blockbuster drug has garnered significant attention from analysts and investors alike.

GUB014295, an amylin analog for obesity, is currently in Phase 1 trials. Join Nic Chahine live on Wednesday, March 19, at 6 PM ET for a step-by-step breakdown of how to to capitalize on post-Fed ...